UK pharmaceutical company Acre Aesthetics Ltd has launched a new hair loss treatment to the UK.
According to the company, the QR 678 Neo is a hair regrowth therapy which treats
the signs of male pattern baldness, hair loss in women, alopecia, and androgenetic causes of hair loss. The product has been approved by the US Food and Drug Administration (FDA) for all the above conditions and contains synergistic biomimetic peptides.
The treatment involves dermarolling and then applying the product to the scalp. The treatment was invented by facial plastic, oculoplastic and cosmetic surgeon Dr Debraj Shome and consultant dermatologist Dr Rinky Kapoor from Mumbai, India.
The hair therapy has been undertaken in multiple clinical trials with published results in
the Journal of Cosmetic and Laser Therapy and Journal of Cosmetic Dermatology. In one trial, 1,000 patients were given intradermal injections into the scalp skin once every three weeks for a total of eight sessions. Hair pull test was performed before every session. A significant reduction in hair fall was seen in 83% of the patients on hair pull test. 75% of the patients believed that the hair injections were aiding the treatment of their hair loss.
Dr Shome said, “Launching the product to the UK market has always been a milestone in our timeline for the product and we couldn’t have picked a more perfect company to do this with. After global success, we hope the UK market sees the uniqueness of the product and buys into
the simplicity of the treatment journey. Now is the right time to launch the product, with
hair loss being even more topical due to more recent recognised symptoms of long COVID-19 coming into play. We have taken time to not only develop the product but also ensure it comes with a catalogue of clinical studies with irrefutable results to assure patient confidence.”
The treatment is now available to clinic owners in the UK.
